Neuphoria Therapeutics (NEUP) Payables (2020 - 2026)
Neuphoria Therapeutics (NEUP) reported Payables of $627185.0 for Q1 2026, down 15.85% year-over-year from $745336.0 in Q1 2025, and up 20.45% on a QoQ basis from $520709.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) has 7 years of Payables data on file, last reported at $627185.0 in Q1 2026.
- Quarterly Payables fell 15.85% year-over-year to $627185.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $627185.0 (down 15.85% YoY) and the FY2025 annual result came in at $1.2 million, down 48.55% from the prior year.
- Payables rose to $627185.0 in Q1 2026 per NEUP's latest filing, from $520709.0 in the prior quarter.
- Across five years, Payables topped out at $2.2 million in Q2 2024 and bottomed at $520709.0 in Q4 2025.
- The 5-year median for Payables is $1.3 million (2024), against an average of $1.3 million.
- The widest annual swing landed in 2022, when Payables soared 151.93%; it then sank 65.98% in 2025.
- Tracing NEUP's Payables over 5 years: stood at $2.0 million in 2022, then tumbled by 30.93% to $1.4 million in 2023, then advanced by 11.04% to $1.5 million in 2024, then slumped by 65.98% to $520709.0 in 2025, then gained by 20.45% to $627185.0 in 2026.
- Per Business Quant, the three latest NEUP Payables figures stand at $627185.0 (Q1 2026), $520709.0 (Q4 2025), and $1.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | 627,185.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 627,185.00 |
| Dec 31, 2025 | 520,709.00 |
| Sep 30, 2025 | 1.37 Mn |
| Jun 30, 2025 | 1.15 Mn |
| Mar 31, 2025 | 745,336.00 |
| Dec 31, 2024 | 1.53 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 2.24 Mn |
| Jun 30, 2023 | 1.38 Mn |
| Jun 30, 2022 | 1.12 Mn |
| Dec 31, 2021 | 2.01 Mn |
| Jun 30, 2021 | 1.40 Mn |
| Jun 30, 2020 | 1.52 Mn |